•  
  •  
 

The Thai Journal of Pharmaceutical Sciences

Abstract

Background and Objectives: Doxorubicin hydrochloride (DOX-HCl), a potent and extensively utilized anticancer medication, faces limitations in skin penetration, resulting in confined effectiveness. Frequent administration leads to resistance at the site of application. This study aims to strike a balance between precision and selectivity to enhance DOX-HCl’s permeation. The goal is to achieve non-invasive drug delivery that avoids issues linked with conventional therapies. This will be achieved through the utilization of patches loaded with transfersomes for drug delivery. Materials and Methods: Transferosomes were prepared through the rotary evaporation technique and optimized by Box-Behnken experimental design. The impact of phospholipid, cholesterol, and tween-80 on drug entrapment efficiency and particle size was assessed using analysis of variance. The resulting formulations underwent characterization involving particle size, zeta potential, transmission electron microscopy, and Fourier-transform infrared spectroscopy. In addition, drug entrapment efficiency, in vitro drug release patterns, ex vivo drug permeation profiles, and histopathological evaluations of the optimized formulations were conducted. Results: The particle size ranged from 53 to 168 nm, with drug entrapment efficiency ranging from 30.8 ± 0.06 to 87.90 ± 0.02%. The optimum formulation exhibited a zeta potential of −24.9 mV and achieved an approximately four-fold increase in permeation rate compared to a pure drug suspension. Histopathological studies of rat abdominal skin samples post-treatment with transferosomes patch indicate a moderate epidermal inflammation versus normal morphology for untreated skin. Conclusion: Utilizing transferosomes in transdermal drug delivery systems (TDDS) presents a promising strategy to address challenges associated with conventional therapies. By incorporating transferosomes into patches, this approach offers a multi-faceted solution to enhance non-invasive drug delivery.

DOI

10.56808/3027-7922.2907

Share

COinS